Weight loss jabs could start a “revolution” in cancer care — slashing cases and deaths, world-leading experts suggest. The likes of Ozempic and Wegovy can cut the risk of obesity-related cancers by a fifth and bowel cancer by half, according to breakthrough research. Trial results presented at the world’s largest cancer conference found breast cancer patients who took the class of drugs were a third less likely to be dead five years later.
Doctors say it will be the “icing on the cake” if the medicines, which have been shown to cut heart attack and strokes, had a comparable effect on cancer. Journalism for the curious Australian across politics, business, culture and opinion. Significantly, they believe there are “multiple ways” they help lessen the risks of cancer, in addition to the weight loss they are famed for.
The GLP-1 agonist drugs, a new class of medications which include Ozempic and Wegovy, featured in several pieces of research presented at the world’s largest cancer conference. Scientists at Case Western Reserve University (CWRU) in the US studied data from more than 34,000 obese patients and found the drugs could “delay or prevent” cancer. Researchers looked at the 13 different types of cancer with proven links to obesity, including breast, bowel and liver cancer.
They found rates of obesity-related cancer were 19 per cent lower for those who took the drugs for at least a year compared to those who didn’t. When other health benefits were f.
